Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,002,187 papers from all fields of science
Search
Sign In
Create Free Account
Src/tubulin Inhibitor KX02
Known as:
KX02
, KX2-361
A lipophilic, orally available inhibitor of both Src kinase activity and tubulin polymerization, with potential antineoplastic activity. Upon oral…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Microtubule Process
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma
M. Ciesielski
,
Yahao Bu
,
+6 authors
R. Fenstermaker
Journal of Neuro-Oncology
2018
Corpus ID: 52306819
PurposeA major challenge to developing new therapies for patients with malignant brain tumors is that relatively few small…
Expand
2010
2010
Abstract 5598: KX02, a novel therapeutic for glioma
M. Ciesielski
,
S. Munich
,
+4 authors
R. Fenstermaker
2010
Corpus ID: 71769868
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Objectives: Over 20,000 new cases of primary…
Expand
2006
2006
NORMAL CONDUCTING HIGH-GRADIENT STUDIES AT KEK
T. Higo
,
M.Akemoto
,
+7 authors
K. Yokoyama
2006
Corpus ID: 56045547
Normal-conducting high-frequency high-field studies have been pursued at XTF, which is a high power X-band RF facility of KEK…
Expand
2004
2004
PROGRESS TOWARD NLC/GLC PROTOTYPE ACCELERATOR STRUCTURES*
C. Adolphsen
,
G. Bowden
,
+25 authors
N. Solyak
2004
Corpus ID: 53491193
The accelerator structure groups for NLC (Next Linear Collider) and GLC (Global Linear Colliders) have successfully collaborated…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE